8-K: Kineta Reopens Enrollment for VISTA-101 Cancer Trial Amidst TuHURA Acquisition Discussions

Kineta has reopened enrollment for its VISTA-101 Phase 1/2 clinical trial, evaluating KVA12123, a VISTA blocking antibody, in patients with advanced solid tumors, while TuHURA Biosciences conducts due diligence for a potential acquisition.

Summary

• Kineta has resumed patient enrollment in its VISTA-101 Phase 1/2 clinical trial, which is testing the KVA12123 antibody as a monotherapy and in combination with Merck's Keytruda for advanced solid tumors.
• The trial has enrolled 30 of the planned 39 patients, and Kineta anticipates full enrollment by the end of 2024.
• KVA12123 has progressed through multiple dose levels and cohorts, showing initial results of partial response and stable disease in combination cohorts, and durable stable disease in monotherapy cohorts.
• The drug has demonstrated a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome.
• TuHURA Biosciences is currently conducting due diligence for a potential acquisition of Kinetas KVA12123 assets, with an exclusivity period extending to October 1, 2024, potentially extendable by 20 days.
• TuHURA and Kintara are also in the process of merging, with the combined company expected to operate under the name TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker HURA.
• The merger is expected to close in the third quarter of 2024, pending customary closing conditions and stockholder approval.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the resumption of the clinical trial, promising initial results, and the potential merger. However, there are also risks and uncertainties associated with the merger and the potential acquisition, which temper the overall sentiment.

Positives

• The VISTA-101 trial has resumed enrollment, indicating progress in the development of KVA12123.
• Initial results for KVA12123 show promising signs of efficacy, including partial response and stable disease.
• KVA12123 has demonstrated a favorable safety and tolerability profile with no dose-limiting toxicities or cytokine release syndrome.
• The potential acquisition of KVA12123 by TuHURA could strengthen their oncology pipeline.
• The merger between TuHURA and Kintara is expected to create a company with a diversified late-stage oncology pipeline.

Negatives

• The merger between TuHURA and Kintara is subject to customary closing conditions, including stockholder approval, which introduces uncertainty.
• There is a risk that Kineta and TuHURA may not enter into a definitive agreement for the acquisition of KVA12123.
• The success of the combined business of TuHURA and Kintara is not guaranteed.

Risks

• The merger between Kintara and TuHURA may not be completed if conditions are not met, including failure to obtain stockholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• The combined company may face challenges in estimating operating expenses and merger-related costs.
• The merger could be terminated due to unforeseen events or circumstances.
• The announcement of the merger could negatively impact the business relationships of both companies.
• There is a risk of legal proceedings related to the merger.
• The combined company may face challenges in protecting their intellectual property rights.
• The combined company may face competitive responses to the merger.
• There is a risk that Kineta and TuHURA do not enter into a definitive agreement for a strategic transaction regarding KVA12123.

Future Outlook

The combined company is expected to focus on advancing TuHURA's personalized cancer vaccine(s) and bi-functional ADCs, with the merger expected to close in the third quarter of 2024. Kineta anticipates full enrollment in the VISTA-101 trial by the end of 2024.

Management Comments

• Dr. James Bianco, CEO of TuHURA, stated that KVA12123 has the potential to be a promising new treatment alternative for patients with cancer and could be a promising addition to their pipeline.
• Thierry Guillaudeux, CSO of Kineta, said they are very pleased to resume enrollment for VISTA-101 and are focused on the successful execution and working towards completing enrollment by the end of 2024.

Industry Context

This announcement reflects the ongoing trend of consolidation and strategic partnerships in the biotech industry, particularly in the immuno-oncology space. The potential acquisition of KVA12123 by TuHURA highlights the interest in novel checkpoint inhibitors and the development of combination therapies to overcome resistance to current immunotherapies. The merger between TuHURA and Kintara is another example of companies combining resources to advance their pipelines and achieve greater scale.

Comparison to Industry Standards

• The VISTA-101 trial is evaluating KVA12123, a VISTA blocking antibody, which is a relatively new target in immuno-oncology compared to more established targets like PD-1/PD-L1.
• Other companies like Jounce Therapeutics and Immutep have also been developing VISTA-targeting therapies, but KVA12123 is differentiated by its unique epitope binding and optimized IgG1 Fc region, which aims to avoid the issues of poor monotherapy activity or cytokine release syndrome seen in other VISTA-targeting therapies.
• The reported initial results of partial response and stable disease in the combination cohorts are encouraging, as many checkpoint inhibitors have shown limited efficacy as monotherapies, highlighting the importance of combination approaches.
• The safety profile of KVA12123, with no dose-limiting toxicities or cytokine release syndrome, is a positive differentiator compared to some other immunotherapies that have faced safety challenges.

Stakeholder Impact

• Shareholders of Kintara and TuHURA will be impacted by the proposed merger, which requires their approval.
• Patients with advanced solid tumors may benefit from the development of KVA12123 and other therapies in the combined company's pipeline.
• Employees of Kintara and TuHURA will be affected by the merger, with potential changes in roles and responsibilities.
• The merger could impact the competitive landscape for other companies in the immuno-oncology space.

Next Steps

• Kineta will continue to enroll patients in the VISTA-101 trial, aiming for full enrollment by the end of 2024.
• TuHURA will continue its due diligence process for the potential acquisition of KVA12123.
• Kintara and TuHURA will work towards completing the merger, pending stockholder approval and other closing conditions.
• The combined company will focus on advancing TuHURA's personalized cancer vaccine(s) and bi-functional ADCs.

Key Dates

Keywords

KVA12123, VISTA-101, Kineta, TuHURA, Kintara, Merger, Clinical Trial, Immunotherapy, Oncology, Checkpoint Inhibitor, Cancer, Acquisition